Search PubMed⌕ Search

Biomedical subjects

M Schnaidt

Publications and source records attributed to M Schnaidt.

28 records · Page 2Linked to original sources
PubMed1992

Thrombocytopenia in the HELLP syndrome is not due to platelet-associated IgG (PAIgG).

The presence of membrane-bound and circulating platelet-associated IgG (PAIgG) in nine pregnant women with hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome) was investigated. The reference group consisted of 21 patients with chronic idiopathic thrombocytopenic purpura (ITP). In the majority of patients with ITP, thrombocytopenia results from the binding of PAIgG to the platelet membrane with subsequent platelet destruction. In none of the patients with HELLP syndrome membrane-bound or circulating PAIgG was found. By contrast, membrane-bound and circulating PAIgG was detected in 15 of the 21 cases of chronic ITP (71.4%). These findings suggest that platelet destruction in patients with HELLP syndrome does not result from the binding of PAIgG to the platelet membrane. Therefore, the treatment of thrombocytopenia in this syndrome with immunosuppressants (e.g., corticosteroids), as in chronic ITP, does not seem appropriate.

Alanine Transaminase↗
PubMed1983

[Treatment of idiopathic thrombocytopenic purpura in adults with high-dosage immunoglobulins].

Four of five patients with idiopathic thrombocytopenic purpura (ITP) responded to high-dose immunoglobulin treatment with transitory rise in platelet count to normal values, while the fifth had only minimal improvement. In the individual case there was good correlation between serum-IgG concentration and platelet count, but an influence on platelet-associated IgG could not be demonstrated with certainty. Treatment with high-dose IgG is apparently particularly suitable for patients with ITP refractory to steroids or splenectomy, in whom bleeding complications or operative procedures make a transitory rise in platelet count desirable.

Adult↗
PubMed1981

The platelet adhesion immunofluorescence test: a modification of the platelet suspension immunofluorescence test.

Platelets can adhere to surfaces by forming pseudopods. This ability is made use of here to simplify conventional platelet suspension immunofluorescence tests, since steps like serum and FITC incubations, washing and microscopic evaluation are done on platelets adhered to glass surfaces. By eliminating time-consuming manipulations like washing in individual test tubes and mounting platelets to microscopic slides, large scale studies can now be performed (up to 480 tests per day and technician). Antibodies can be detected with fresh as well as with frozen platelets from a well defined cell panel. The PAIFT is 2 to 3 times more sensitive than the NIH-standard-micro-lymphocytotoxicity-test (NIH-LCT), thus allowing earlier recognition of alloimmunization of patients.

Female↗
PubMedDate not supplied

[Pregnancy monitoring and labor planning in PLA1-induced neonatal alloimmunothrombocytopenia].

Alloimmune thrombocytopenia in newborns may lead to severe bleeding. Most often this thrombocytopenia is caused by incompatibility in the PlA system (mother PlA1 negative, child PlA1 positive). If the mother produces antibodies against PlA1 which cross the placenta, they will then destroy the child's platelets. Recent investigations have shown a strong correlation between HLA-DR3 and production of antibody. Since no screening for such antibodies is performed during pregnancy the resulting thrombocytopenia in the newborn will always be a sudden event. The best therapy is transfusion of PlA1 negative platelets; if no PlA1 negative donor can be found (2.25% of all donors) platelet concentrates of the mother may be used. After diagnosis of PlA related thrombocytopenia the relatives of the mother should be tested for PlA for the following reasons: 1. to determine PlA1 negative relatives to be used as possible donors in future pregnancies, and 2. to detect PlA1 negative women of child bearing age. If pregnant these women should be HLA-DR typed and followed for anti PlA1 antibodies to estimate the risk for the child and to determine further procedures, for instance sectio caesarea to avoid intracranial bleeding during birth.

Adult↗